WO1995004520A1 - Method and composition for treating muco-epidermal and epidermal pain, inflammation and infection - Google Patents
Method and composition for treating muco-epidermal and epidermal pain, inflammation and infection Download PDFInfo
- Publication number
- WO1995004520A1 WO1995004520A1 PCT/US1994/008944 US9408944W WO9504520A1 WO 1995004520 A1 WO1995004520 A1 WO 1995004520A1 US 9408944 W US9408944 W US 9408944W WO 9504520 A1 WO9504520 A1 WO 9504520A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- epidermal
- preparation
- steroidal anti
- inflammatory agent
- chlorhexidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/43—Guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
- A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
Definitions
- the present invention relates generally to pharmaceutical preparations for the treatment of muco-epidermal and epidermal tissue. More particularly, the present invention relates to gels, creams, solutions and other topical preparations including a mixture of chlorhexidine and at least one non-steroidal anti-inflammatory agent. The invention further provides a method for the treatment of muco-epidermal and epidermal tissue using such preparations.
- chlorhexidine gels, rinses and creams are routinely used to control bacterial infections on mucosal epidermal and epidermal tissue.
- chlorhexidine gels and rinses are widely used in dentistry for the treatment of periodontal disease.
- Non-steroidal anti-inflammatory agents such as ibuprofen, ketoprofen and indomethacin have application in the treatment of, for example, inflammatory diseases such as arthritis, general muscle, skeletal and joint pain and menstrual cramps.
- a pharmaceutical preparation including a combination of chlorhexidine and at least one anti-inflammatory agent which together show a synergistic effect in the treatment of muco-epidermal and epidermal inflammation and infection.
- the present invention meets the above-stated objects and others that will become readily apparent by providing topical pharmaceutical preparations which include chlorhexidine and at least one non-steroidal anti-inflammatory agent. These active ingredients are incorporated into a gel, cream, solution, rinse or other pharmaceutically acceptable carrier and are applied topically to sites of epidermal and muco-epidermal inflammation, infection or lesion.
- the preparations which are the subject of the present invention include a non-toxic amount of chlorhexidine and preferably include, as the non-steroidal anti-inflammatory agent, indomethacin, ibuprofen, ketoprofen or other prostaglandin inhibitors.
- chlorhexidine and a non-steroidal anti-inflammatory agent unexpectedly show a synergistic effect in the treatment of a number of conditions including, periodontal disease, acne, post-radiation therapy, post- chemotherapy therapy, post-surgical therapy, burns and non-specific epidermal and muco-epidermal infections.
- the present invention is also directed to a method for treating epidermal and muco-epidermal tissue employing the above-described topical preparations.
- the course of therapy with such preparations generally requires one to three applications per day or is applied on an as needed basis, depending on the severity of the condition.
- Treatment includes directly applying the topical preparations to the affected site.
- the-topical pharmaceutical preparations of the present invention include chlorhexidine in a therapeutically effective amount. For most therapies, from about 0.1 wt.% to about 1.0 wt.%, preferably about 0.2 wt.% of chlorhexidine, has been found to be effective.
- the preparations further include a non-toxic amount of at least one non-steroidal anti- inflammatory agent, most preferably indocin, ibuprofen and/or ketoprofen, in an amount ranging from about 2 wt.% to about 5 wt.% of the total preparation.
- the active ingredients are incorporated into a solution, cream, rinse, lotion, gel or other acceptable carrier.
- the active ingredients are first solubilized and then incorporated into the carrier.
- a suspending agent such as, for example, acacia powder, xanthan gum, methylcellulose, hydroxymethylcellulose or hydroxypropylcellulose, has been found to be particularly useful when compounding the carrier.
- hydroxymethylcellulose gel is the preferred carrier where treatment requires manual application of the preparation to affected epidermal or muco-epidermal tissue.
- Example II Two surgical patients were instructed to apply the preparation described in Example I to post surgical sites twice a day for seven days. In both cases pain, inflammation and infection at the affected sites were relieved.
- Example II Three patients exhibiting acne sores were instructed to apply the preparation described in Example I to the affected sites twice a day for seven days. In all cases, treatment with the preparations provided a reduction in the pain and inflammation associated with the sores.
- Example I One patient undergoing radiation therapy and two patients undergoing chemotherapy were each instructed to apply the preparation described in Example I twice daily for one week. All three patients received relief from pain and showed faster healing rates of intraoral tissues following treatment with the prescribed preparations.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94924605A EP0664695A1 (en) | 1993-08-06 | 1994-08-08 | Method and composition for treating muco-epidermal and epidermal pain, inflammation and infection |
JP7506565A JPH08505402A (en) | 1993-08-06 | 1994-08-08 | Method for treating mucosal epidermal and epidermal pain, inflammation and infectious disease and therapeutic composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10328993A | 1993-08-06 | 1993-08-06 | |
US08/103,289 | 1993-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995004520A1 true WO1995004520A1 (en) | 1995-02-16 |
Family
ID=22294404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/008944 WO1995004520A1 (en) | 1993-08-06 | 1994-08-08 | Method and composition for treating muco-epidermal and epidermal pain, inflammation and infection |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0664695A1 (en) |
JP (1) | JPH08505402A (en) |
CA (1) | CA2146547A1 (en) |
WO (1) | WO1995004520A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999015165A1 (en) * | 1997-09-22 | 1999-04-01 | Biocontrol Incorporated | Topical non-steroidal anti-inflammatory drug composition |
WO2002064127A1 (en) * | 2001-02-15 | 2002-08-22 | Biointeractions Ltd | Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
FR2822070A1 (en) * | 2001-03-15 | 2002-09-20 | Andre Salkin | Treatment of adolescence associated skin disorders, e.g. acne or inflammatory lesions, using cosmetic or pharmaceutical composition containing low concentrations of biguanide and pyrimidine compounds |
US7771743B1 (en) | 1999-05-01 | 2010-08-10 | Biointeractions, Ltd. | Infection resistant polymers, their preparation and uses |
RU2491061C2 (en) * | 2011-12-05 | 2013-08-27 | Елена Николаевна Светлакова | Agent for local treatment of periodontal diseases |
EP2698149A1 (en) | 2012-08-17 | 2014-02-19 | Sanovel Ilac Sanayi ve Ticaret A.S. | Topical Aqueous Pharmaceutical Compositions of Flurbiprofen and Chlorhexidine |
US8865198B2 (en) | 2010-10-25 | 2014-10-21 | Dexcel Pharma Technologies Ltd. | Method for treating a periodontal disease |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2812192B1 (en) * | 2000-07-28 | 2003-01-31 | Oreal | USE OF PROSTAGLANDIN EP-3 RECEPTOR ANTAGONISTS AS A COSMETIC AGENT FOR MITIGATING, REDUCING OR STOPPING HAIR AND HAIR LOSS |
FR2812190B1 (en) * | 2000-07-28 | 2003-01-31 | Oreal | USE OF NON-PROSTANOIC AGONISTS OF EP-2 AND / OR EP-4 PROSTAGLANDIN RECEPTORS AS A COSMETIC AGENT FOR MITIGATING, DECREASING OR STOPPING HAIR AND HAIR LOSS |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4740365A (en) * | 1984-04-09 | 1988-04-26 | Toyo Boseki Kabushiki Kaisha | Sustained-release preparation applicable to mucous membrane in oral cavity |
US4767751A (en) * | 1984-01-25 | 1988-08-30 | Beecham Group P.L.C. | Topical drug release system |
US4789667A (en) * | 1984-09-03 | 1988-12-06 | Teijin Limited | External pharmaceutical composition and methods of use |
US4814176A (en) * | 1985-01-11 | 1989-03-21 | Teijin Ltd. | Sustained release preparation |
US4906670A (en) * | 1986-03-25 | 1990-03-06 | Rohto Pharmaceutical Co., Ltd. | Pharmaceutical composition for the treatment of periodontal disease |
US4975271A (en) * | 1988-12-19 | 1990-12-04 | Vipont Pharmaceutical, Inc. | Muscosal delivery systems for treatment of periodontal disease |
US5102666A (en) * | 1990-09-11 | 1992-04-07 | Oramed, Inc. | Calcium polycarbophil controlled release composition and method |
US5230895A (en) * | 1990-05-01 | 1993-07-27 | Copley Pharmaceutical Inc. | Sustained released delivery system for use in the periodontal pocket |
-
1994
- 1994-08-08 JP JP7506565A patent/JPH08505402A/en active Pending
- 1994-08-08 CA CA002146547A patent/CA2146547A1/en not_active Abandoned
- 1994-08-08 WO PCT/US1994/008944 patent/WO1995004520A1/en not_active Application Discontinuation
- 1994-08-08 EP EP94924605A patent/EP0664695A1/en not_active Withdrawn
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4767751A (en) * | 1984-01-25 | 1988-08-30 | Beecham Group P.L.C. | Topical drug release system |
US4740365A (en) * | 1984-04-09 | 1988-04-26 | Toyo Boseki Kabushiki Kaisha | Sustained-release preparation applicable to mucous membrane in oral cavity |
US4789667A (en) * | 1984-09-03 | 1988-12-06 | Teijin Limited | External pharmaceutical composition and methods of use |
US4814176A (en) * | 1985-01-11 | 1989-03-21 | Teijin Ltd. | Sustained release preparation |
US4906670A (en) * | 1986-03-25 | 1990-03-06 | Rohto Pharmaceutical Co., Ltd. | Pharmaceutical composition for the treatment of periodontal disease |
US4975271A (en) * | 1988-12-19 | 1990-12-04 | Vipont Pharmaceutical, Inc. | Muscosal delivery systems for treatment of periodontal disease |
US5230895A (en) * | 1990-05-01 | 1993-07-27 | Copley Pharmaceutical Inc. | Sustained released delivery system for use in the periodontal pocket |
US5102666A (en) * | 1990-09-11 | 1992-04-07 | Oramed, Inc. | Calcium polycarbophil controlled release composition and method |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999015165A1 (en) * | 1997-09-22 | 1999-04-01 | Biocontrol Incorporated | Topical non-steroidal anti-inflammatory drug composition |
US7771743B1 (en) | 1999-05-01 | 2010-08-10 | Biointeractions, Ltd. | Infection resistant polymers, their preparation and uses |
WO2002064127A1 (en) * | 2001-02-15 | 2002-08-22 | Biointeractions Ltd | Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
US6929818B2 (en) | 2001-02-15 | 2005-08-16 | Biointeractions Ltd. | Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
FR2822070A1 (en) * | 2001-03-15 | 2002-09-20 | Andre Salkin | Treatment of adolescence associated skin disorders, e.g. acne or inflammatory lesions, using cosmetic or pharmaceutical composition containing low concentrations of biguanide and pyrimidine compounds |
EP1247521A1 (en) * | 2001-03-15 | 2002-10-09 | André Salkin | Use of biguanide and pyrimidine derivatives for the preparation of a topical skin care composition |
US8865198B2 (en) | 2010-10-25 | 2014-10-21 | Dexcel Pharma Technologies Ltd. | Method for treating a periodontal disease |
US9278064B2 (en) | 2010-10-25 | 2016-03-08 | Dexcel Pharma Technologies Ltd. | Method for treating a periodontal disease |
US9889090B2 (en) | 2010-10-25 | 2018-02-13 | Dexcel Pharma Technologies Ltd. | Method for treating a periodontal disease |
RU2491061C2 (en) * | 2011-12-05 | 2013-08-27 | Елена Николаевна Светлакова | Agent for local treatment of periodontal diseases |
EP2698149A1 (en) | 2012-08-17 | 2014-02-19 | Sanovel Ilac Sanayi ve Ticaret A.S. | Topical Aqueous Pharmaceutical Compositions of Flurbiprofen and Chlorhexidine |
WO2014027976A1 (en) | 2012-08-17 | 2014-02-20 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Topical aqueous pharmaceutical compositions of flurbiprofen and chlorhexidine |
EP2865370A1 (en) | 2012-08-17 | 2015-04-29 | Sanovel Ilac Sanayi ve Ticaret A.S. | Topical aqueous pharmaceutical compositions of flurbiprofen and chlorhexidine |
EP3834815A1 (en) | 2012-08-17 | 2021-06-16 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Topical aqueous pharmaceutical compositions of flurbiprofen and chlorhexidine |
Also Published As
Publication number | Publication date |
---|---|
CA2146547A1 (en) | 1995-02-16 |
EP0664695A1 (en) | 1995-08-02 |
JPH08505402A (en) | 1996-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU777821B2 (en) | Therapeutic compositions and methods of use thereof | |
AU609090B2 (en) | Composition for treatment of acne | |
JP2007513162A (en) | Compositions and methods for topical treatment of skin infections | |
WO2009106963A2 (en) | Dental composition for preventing and treating stomatitis and mouth ulcers | |
EP1531837A1 (en) | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions | |
CA2141056C (en) | Treatment of dentoalveolar infections with taurolidine and/or taurultam | |
WO1995004520A1 (en) | Method and composition for treating muco-epidermal and epidermal pain, inflammation and infection | |
EP0988040A1 (en) | Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain | |
US4518583A (en) | Hemorrhoid and anorectal disease treatment method | |
RU2184538C2 (en) | Use of dichlorobenzyl alcohol for preparing medicinal agent for treatment of topical inflammation and medicinal agent comprising dichlorobenzyl alcohol | |
JP2983335B2 (en) | Use of fosfomycin and its pharmaceutically acceptable salts as topical scar forming agents | |
US4985235A (en) | Treatment of periodontoclasia with retinoic acid | |
JPS6054932B2 (en) | therapeutic composition | |
WO1983000628A1 (en) | A method of treating acne vulgaris and composition containing carbamide peroxide | |
US4879106A (en) | Methods for treating gingivitis and paradental pyorrhea | |
JPH07247210A (en) | Composition for oral cavity | |
EP0353675B1 (en) | Treatment of periodontoclasia with retinoic acid | |
JPH0637383B2 (en) | Oral anti-inflammatory agent | |
EP0228137A2 (en) | Anaerobe-selective antibacterial compositions | |
RU2628880C1 (en) | Method for treatment of fast progressing periodontitis (fpp) | |
UA137242U (en) | GEL FOR THE TREATMENT OF DYSTROPHIC-INFLAMMATORY DISEASES OF PERIODONT AND TRAUMATIC LESIONS OF THE ORAL MUCOUS | |
WO1987003476A1 (en) | Composition for the treatment of periodontal disease | |
CA2379653A1 (en) | Pharmaceutical composition for topical application, uses and process for the preparation thereof | |
RU2137461C1 (en) | Composition for treatment of mouth cavity sicknesses | |
WO1998027968A1 (en) | Novel topical formulation of anti-inflammatory drugs for the treatment of localized pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2146547 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994924605 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1994924605 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994924605 Country of ref document: EP |